Phase 1 Study of No-Carrier Added 177Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor–Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose To provide a wider choice of treatment opportunities for patients with neuroendocrine tumor (NET) in Korea, we have conducted a phase 1, open-label, single-arm, dose-escalation study of SNU-KB-01, a no-carrier added (NCA) <sup>177</sup>Lu-labeled DOTATATE.Materials and Methods Seven patients with inoperable, progressive, metastatic, or locally advanced, somatostatin receptor-positive NET with Ki67 index ≤ 20% were enrolled according to the rolling six design. The study consisted of two cohorts to receive 4 cycles of SNU-KB-01 every 8 weeks for the first dose of 5.55 GBq (n=3) and 7.40 GBq (n=4). We assessed the incidence of dose-limiting toxicity (DLT) and adverse event, absorbed dose of kidneys and bone marrow, and objective tumor response.Results Seven patients completed 4 cycles (21.3-30.1 GBq total dose) of SNU-KB-01. The mean absorbed doses to kidneys and bone marrow were 0.500 mGy/MBq and 0.053 mGy/MBq, respectively, and the total body effective dose was 0.115 mSv/MBq. No DLT was observed and the maximum tolerated dose was 7.40 GBq/cycle. Grade 3 thrombocytopenia occurred in one patient, but no other grade 3 or 4 major hematologic or renal toxicity was observed. The best objective response to SNU-KB-01 was partial response. Overall response rate was 42.9% and disease control rate was 85.7%.Conclusion Treatment with 4 cycles of SNU-KB-01 was well tolerated and resulted in control of disease in most of the patients. Our results indicate SNU-KB-01, an NCA <sup>177</sup>Lu-labeled DOTATATE, as a potentially safe and efficacious treatment option for NET patients in Korea.
Abstract
Purpose To provide a wider choice of treatment opportunities for patients with neuroendocrine tumor (NET) in Korea, we have conducted a phase 1, open-label, single-arm, dose-escalation study of SNU-KB-01, a no-carrier added (NCA) <sup>177</sup>Lu-labeled DOTATATE.Materials and Methods Seven patients with inoperable, progressive, metastatic, or locally advanced, somatostatin receptor-positive NET with Ki67 index ≤ 20% were enrolled according to the rolling six design. The study consisted of two cohorts to receive 4 cycles of SNU-KB-01 every 8 weeks for the first dose of 5.55 GBq (n=3) and 7.40 GBq (n=4). We assessed the incidence of dose-limiting toxicity (DLT) and adverse event, absorbed dose of kidneys and bone marrow, and objective tumor response.Results Seven patients completed 4 cycles (21.3-30.1 GBq total dose) of SNU-KB-01. The mean absorbed doses to kidneys and bone marrow were 0.500 mGy/MBq and 0.053 mGy/MBq, respectively, and the total body effective dose was 0.115 mSv/MBq. No DLT was observed and the maximum tolerated dose was 7.40 GBq/cycle. Grade 3 thrombocytopenia occurred in one patient, but no other grade 3 or 4 major hematologic or renal toxicity was observed. The best objective response to SNU-KB-01 was partial response. Overall response rate was 42.9% and disease control rate was 85.7%.Conclusion Treatment with 4 cycles of SNU-KB-01 was well tolerated and resulted in control of disease in most of the patients. Our results indicate SNU-KB-01, an NCA <sup>177</sup>Lu-labeled DOTATATE, as a potentially safe and efficacious treatment option for NET patients in Korea.
참고문헌 (26)
- Raut CP, "Carcinoid tumors", Curr Probl Surg, 43, pp.383~450 (2006)
- Yao JC, "One hundred years after"carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States", J Clin Oncol, 26, pp.3063~3072 (2008)
- -octreotide : the Rotterdam experience with more than 1000 patients, "Eur J Nucl Med", 1993, 716~731
- Krenning EP, "Radiolabelled somatostatin analogue(s)for peptide receptor scintigraphy and radionuclide therapy", Ann Oncol, 10(Suppl 2), pp.S23~9 (1999)
- -TOC in metastasized neuroendocrine cancers, "J Clin Oncol", 2011, 2416~2423
- octreotate : toxicity, efficacy, and survival, "J Clin Oncol", 2008, 2124~2130
- Bodei L, "Peptide receptor radionuclide therapy with(1)(7)(7)Lu-DOTATATE : the IEO phase I-II study", Eur J Nucl Med Mol Imaging, 38, pp.2125~2135 (2011)
- Bodei L, "The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy(PRRNT)in neuroendocrine tumours", Eur J Nucl Med Mol Imaging, 40, pp.800~816 (2013)
- Strosberg J, "Phase 3 trial of(177)Lu-dotatate for midgut neuroendocrine tumors", N Engl J Med, 376, pp.125~135 (2017)
- Skolnik JM, "Shortening the timeline of pediatric phase I trials : the rolling six design", J Clin Oncol, 26, pp.190~195 (2008)
- Coleman CN, "Molecular and cellular biology of moderatedose(1-10 Gy)radiation and potential mechanisms of radiation protection : report of a workshop at Bethesda, Maryland, December 17-18, 2001", Radiat Res, 159, pp.812~834 (2003)
- Emami B, "Tolerance of normal tissue to therapeutic irradiation", Int J Radiat Oncol Biol Phys, 21, pp.109~122 (1991)
- Delpassand ES, "Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors : the first US phase 2 experience", Pancreas, 43, pp.518~525 (2014)
- Ashutosh Dash, "Production of 177Lu for Targeted Radionuclide Therapy: Available Options", Nuclear Medicine and Molecular Imaging, 49(2), pp.85~107 (2015), 대한핵의학회
- Verberne HJ, "Clinical performance and radiation dosimetry of no-carrier-added vs carrier-added 123I-me-taiodobenzylguanidine(MIBG)for the assessment of cardiac sympathetic nerve activity", Eur J Nucl Med Mol Imaging, 35, pp.798~807 (2008)
- Limouris G, "Progression free survival and response rate differences between non-carrier added(nca)and carrier added(ca)177 Lu-DOTATATE. In : Non-functioning NET(NFNET)liver metastasized, treated patient", Eur J Nucl Med Mol Imaging, 45(Suppl 1), pp.S595~ (2018)
- Lutathera European Public Assessment Report, , European Medicines Agency, ~, pp.EMA (2017), 506460[DOI]
- Ciesla B, "Hematology in practice" (2012), F.A. Davis Company
- Heylmann D, "Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells", Biochim Biophys Acta, 1846, pp.121~129 (2014)
- Kong G, "Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma", J Clin Endocrinol Metab, 102, pp.3278~3287 (2017)
- Gains JE, "177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma", J Nucl Med, 52, pp.1041~1047 (2011)
- Marincek N, "Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma : long-term results of a phase II clinical trial", J Nucl Med, 56, pp.171~176 (2015)
- Parghane RV, "Clinical utility of(177)Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity", Head Neck, 42, pp.401~416 (2020)
- Zidan L, "Efficacy and safety of(177)Lu-DOTATATE in lung neuroendocrine tumors : a bicenter study", J Nucl Med, 63, pp.218~225 (2022)
- Giuffrida G, "Peptide receptor radionuclide therapy for aggressive pituitary tumors : a monocentric experience", Endocr Connect, 8, pp.528~535 (2019)
- Lee MS, "Whole-body voxel-based personalized dosimetry : the multiple voxel S-value approach for heterogeneous media with nonuniform activity distributions", J Nucl Med, 59, pp.1133~1139 (2018)